Back to Journals » Therapeutics and Clinical Risk Management » Volume 15

Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence

Authors Korzeniowska K, Jankowski J, Cieślewicz A, Jabłecka A

Received 15 May 2019

Accepted for publication 25 July 2019

Published 9 September 2019 Volume 2019:15 Pages 1095—1110


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh

Katarzyna Korzeniowska, Jerzy Jankowski, Artur Cieślewicz, Anna Jabłecka

Department of Clinical Pharmacology, Poznan University of Medical Sciences, Poznan 61-848, Poland

Correspondence: Artur Cieślewicz
Department of Clinical Pharmacology, Poznan University of Medical Sciences, Długa 1/2 Str., Poznan 61-848, Poland
Tel +48 61 854 9216
Fax +48 61 853 3161
Email [email protected]

Abstract: Cardiovascular diseases and cancer are the most common death causes in the USA and Europe. Moreover, many patients suffer from both of these conditions – a situation which may result from cardiotoxicity of anticancer treatment. In order to reduce the severity of this adverse effect, various methods have been proposed, including the usage of new drug forms and less toxic analogs, omitting the combinations of potentially cardiotoxic drugs and introducing potential cardioprotective agents to the therapy. However, prevention of cardiotoxicity still seems to be insufficient. The article reviews the results of current studies on the use of cardiovascular drugs in the prevention of cardiotoxicity. Based on this knowledge, the most promising cardioprotective drugs seem to be carvedilol, nebivolol, enalapril, and candesartan, as they prevent heart remodeling and correct elevated resting heart rate, which directly affects mortality. Alternatively, in case of adverse reactions, statins might be considered.

Keywords: chemotherapy, cardiotoxicity, heart failure, prevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]